The clinical value of serum GPC3 level in predicting recurrence of patients with primary hepatocellular carcinoma / 中华预防医学杂志

Objective: To investigate the clinical value of serum glypican-3 (GPC3) detection in predicting recurrence of primary hepatocellular carcinoma (HCC). Methods: Through univariate and multivariate logistic regression analysis, the patients pathologically diagnosed with HCC in our hospital from March 2019 to January 2021 were enrolled as the experimental group (n=113), and patients with follow-up time longer than 6 months were included in the prognosis group(n=64). At the same time,20 healthy individuals and 20 individuals with benign liver disease from the physical examination center were enrolled by simple random sampling as control group (n=40). The serum GPC3 and alpha-fetoprotein (AFP) levels were respectively detected by ELISA and chemiluminescence. Then, the study explored the influential factors of the recurrence in HCC patients and constructed the HCC-GPC3 recurrence predicting model by logistic regression. Results: In the research, the sensitivity of GPC3 for the diagnosis of HCC was 61.95% (70/113) and AFP was 52.21% (59/113), meanwhile, the specificity of GPC3 could reach 87.50% (35/40) and AFP was 90.00% (36/40),respectively; The serum GPC3 levels of HCC patients with progressive stage, tumor size≥3 cm, vascular cancer thrombosis and portal venous thromboembolism were significantly higher than that of HCC patients with early stage, tumor size<3 cm, vascular cancer thrombosis and portal venous thromboembolism (Z=2.677, 2.848, 2.995, 2.252, P<0.05), independent of different ages, presence or absence of ascites, peritoneal metastasis, cirrhosis, intrahepatic metastasis (Z=-1.535, 1.011, 0.963, 0.394, 1.510, P>0.05), respectively. Univariate analysis showed that there were no statistically significant differences between the recurrence group and the non-recurrence group in terms of different age, tumor size, presence or absence of vascular cancer thrombosis, ascites, peritoneal metastasis, cirrhosis and AFP levels (χ2=2.012, 0.119, 2.363, 1.041, 0.318, 0.360, Z=0.748, P>0.05); The ratio of those with the progressive stage, portal venous thromboembolism and intrahepatic metastasis and GPC3 levels were all higher in the recurrence group than in the non-recurrence group (χ2=4.338, 11.90, 4.338, Z=2.805, P<0.05).Including the above risk factors in the logistic regression model, the logistic regression analysis showed that the stage, the presence of portal venous thromboembolism,intrahepatic metastasis and GPC3 levels were correlated with the prognosis recurrence of HCC patients (Wald χ2 =4.421, 5.681, 4.995, 4.319, P<0.05), and the HCC-GPC3 recurrence model was obtained as: OcScore=-2.858+1.563×[stage]+1.664×[intrahepatic metastasis]+2.942×[ portal venous thromboembolism]+0.776×[GPC3]. According to the receiver operating characteristic curve(ROC), the area under the curve(AUC)of the HCC-GPC3 prognostic model was 0.862, which was better than that of GPC3 alone (AUC=0.704). The cut-off value of model SCORE was 0.699 (the cut-off value of GPC3 was 0.257 mg/L), furthermore, the total sensitivity and specificity of model were 83.3% and 82.4%, which were better than those of GPC3(60.0% and 79.4%).Kaplan-Meier showed that the median PFS was significantly shorter in HCC patients with high GPC3 levels (≥0.257 mg/L) and high values of the model SCORE (≥0.700) (χ2=12.73, 28.16, P<0.05). Conclusion: Besides diagnosing of HCC, GPC3 can may be an independent risk indicator for the recurrence of HCC and can more efficiently predicting the recurrence of HCC patients when combined with the stage, the presence or absence of intrahepatic metastasis and portal venous thromboembolism.

Effect of down-regulation of HE4 gene expression on biologic behavior of ovarian cancer cells / 中华病理学杂志

<p><b>OBJECTIVE</b>To investigate the effects of HE4 gene knockdown on the proliferation, adhesion and invasion of the ovarian cancer cells SKOV3.</p><p><b>METHODS</b>The knockdown of HE4 gene was performed by RNAi technology. The recombinant plasmids (pSUPER-HE4 shDNAs) were constructed and transfected into human ovarian cancer cells SKOV3. HE4 expression was then identified by real-time PCR and Western blot analysis. The invasion and adhesion ability of transduced cells were determined. In addition, cell proliferation and growth were analyzed by colonies formation assay.</p><p><b>RESULTS</b>Knockdown of HE4 was achieved, and further confirmed by real-time PCR and Western blot. The proliferation of HE4-down-regulated cells was not affected, but the invasion ability of the transfected cells was reduced (P < 0.05) and the adhesion ability was also reduced to 27.3%.</p><p><b>CONCLUSION</b>HE4 expression is down-regulated effectively by the constructed HE4 shDNA, and thus knockdown of HE4 inhibits the adhesion and invasion of SKOV3 cells.</p>

Expression of a novel biomarker, MR-1S, in ovarian carcinoma and its biological significance / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To investigate the expression of a novel biomarker, human short-type myofibrillogenesis regulator-1 (MR-1S), in ovarian carcinoma and explore its biological significance.</p><p><b>METHODS</b>The MR-1S mRNA levels were analyzed by reverse transcription polymerase chain reaction (RT-PCR) in 23 specimens of ovarian cancers and 20 specimens of control ovarian tissues. The expression of MR-1S in these specimens was detected by real-time PCR and immunohistochemical analysis. In addition, the expression of MR-1S in ovarian cancer SKOV3 cells was determined by immunocytochemisty. MR-1S mRNA and protein level of SKOV3 cells was compared in the two groups treated by carboplatin and paclitaxel at 24 h, 48 h and 72 h, respectively. Furthermore, the expression of MR-1S was analyzed in liner concentration range of the anti-cancer drug, and the potential relation between MR-1S expression and cell apoptosis rate was predicted.</p><p><b>RESULTS</b>The level of MR-1S mRNA was significantly higher in ovarian cancer tissues than those of control tissues by RT-PCR and Real-time PCR analysis. MR-1S protein was overexpressed in ovarian cancer tissues with a positive rate of 78.3% (18/23) than that in the control tissues (30.0%, P<0.05) through IHC analysis. The expression of MR-1S was markedly decreased by treatment with carboplatin and paclitaxel, and there was a direct correlation between MR-1S expression and apoptosis rate, especially in a liner concentration range of paclitaxel at 48 h.</p><p><b>CONCLUSION</b>MR-1S is highly expressed in ovarian cancer cells and tissues, and it may be a promising biomarker for diagnosis and a new target for ovarian cancer therapy.</p>

Preliminary application on test paper of gold-labelled antibody against fibronectin EIIIA splicing variant / 法医学杂志

OBJECTIVE@#To develop the test Paper of gold-labelled antibody against fibronectin EIIIR A splicing variant, which can be available in forensic wound interval estimation.@*METHODS@#Two sensitive antibodies were compared with enzyme link immunoabsorband assay (ELISA). After colloid gold labeled, the effects of the two antibodies were tested by methods of Dot immunogold filtration assay and gold immunochromatography assay, respectively. The test paper was finally appraised by applied in experimental skin injury in rats.@*RESULTS@#On the test paper, detected line appeared in three hours wound age group, and then the darkness of positive staining became darker with injury time prolonging, while control normal skin cannot found to be positive staining.@*CONCLUSION@#The gold-labeled test paper can be useful in estimation of wounding interval in forensic science.